Related Experiment Video
Updated: Jan 12, 2026

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia
Published on: December 4, 2018
Identification and Validation of NDRG2 as a Biomarker for Follicular Lymphoma
Yidong Zhu1, Jun He2, Rong Wei2
1Department of Traditional Chinese Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200072, China.
Introduction:
Follicular lymphoma (FL) is the most prevalent form of indolent lymphoma, characterized by intermittent relapse and remission periods. This study aims to identify potential biomarker genes for FL and elucidate their roles in the disease.
Methods:
FL-related microarray datasets were downloaded from the Gene Expression Omnibus database. Differential expression and weighted gene co-expression network analyses (WGCNA) were conducted to identify potential hub genes. Various machine learning algorithms were applied to improve gene selection accuracy and predictive performance. Mendelian randomization (MR) analysis was carried out to identify genes with causal relationships to FL. Functional enrichment analysis was performed to explore the underlying mechanisms. Finally, the identified biomarker gene was validated in clinical samples using quantitative real-time PCR.
Results:
A total of 60 hub genes were identified through differential expression analysis and WGCNA. Subsequently, 11 characteristic genes were identified using machine learning algorithms. MR analysis revealed 173 genes with causal effects on FL, leading to the identification of one key co-expressed gene, NDRG family member 2 (NDRG2), as a potential biomarker for FL. NDRG2 demonstrated strong predictive performance. Functional enrichment analysis revealed significant associations between NDRG2 and immune-related pathways in FL. Validation in clinical samples confirmed the relevance of NDRG2 as a biomarker.
Discussion:
The integration of machine learning and MR successfully identified NDRG2 as a promising biomarker with a causal relationship to FL. Validation in clinical samples reinforced the reliability of these findings in clinical practice.
Conclusion:
By combining machine learning, MR, and experimental validation, NDRG2 was identified and validated as a promising biomarker for FL.
More Related Videos
06:32Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
Published on: January 9, 2019
11:29HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
Published on: July 20, 2016